Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
01 Septiembre 2023 - 12:00AM
Ipsen announces change in R&D leadership: Howard Mayer to
retire, succeeded by Christelle Huguet
PARIS, FRANCE, 1 September 2023 – Ipsen
(Euronext: IPN; ADR: IPSEY), a global specialty-driven
biopharmaceutical company, announced today the appointment of
Christelle Huguet as Executive Vice President, Head of Research and
Development. She will succeed Howard Mayer, EVP and Head of
R&D, who will leave Ipsen on September 22, following his
decision to retire.
Christelle Huguet will serve on the Executive Leadership Team
(ELT), reporting directly to Ipsen’s Chief Executive Officer, David
Loew and immediately succeeding Howard upon his departure. Since
joining Ipsen in May 2020 as Senior Vice President and Head of
Research, External Innovation and Early Development (REED), she has
built a lean and dynamic global REED organization supporting
Ipsen’s three therapeutic areas: Oncology, Rare Disease and
Neuroscience, from target to clinic.
“I am very pleased that Christelle will join Ipsen’s Executive
Leadership team as we continue to successfully deliver on our
strategic roadmap. Christelle’s deep experience, spanning discovery
and development, will be essential to advance our pipeline and
drive positive developments from external innovation. This
experience, coupled with her passion and leadership style of
developing people, will ensure a smooth transition as she assumes
her new role,” said David Loew, CEO, Ipsen.
“I also want to thank Howard for his significant contributions
to Ipsen. Over the last four years he built a strong R&D
leadership team, which led a deep review of the pipeline,
prioritized disease areas, and identified strategic programs and
opportunities. Howard was also instrumental in Ipsen’s success from
a Business Development and M&A perspective over the last
several years, and he played a pivotal role in the acquisitions and
integrations of Epizyme and Albireo into Ipsen. He has remained
personally committed to bringing much-needed innovation to patients
throughout his distinguished career.”
Christelle brings depth and expertise, with over 25 years of
biotech and industry experience spanning drug discovery and
development from the early phases of drug discovery to the
identification and early clinical development of small molecules
and biologics up to Phase IIb. Prior to joining Ipsen in,
Christelle was Chief Scientific Officer for X-Chem Inc & ZebiAI
Therapeutics, where she built an internal portfolio of oncology
programs and implemented the use of advanced machine learning to
DNA-encoded library data analysis. Prior to X-Chem, she was the
head of internal research at Alexion, where she focused on rare
diseases. Earlier in her career, she spent 18 years at Pfizer in a
number of senior leadership roles in research and pre-clinical
development, including CSO for GU disease, Global Head of PK, PD
and Metabolism, and CSO for inflammation and immunology.
“I know firsthand that our R&D organization is committed to
Ipsen’s ambitious innovation agenda,” said Christelle Huguet. “I’m
honored to lead this talented team to continue to bring much-needed
new medicines in Oncology, Rare Disease and Neuroscience, where we
can make a meaningful impact for patients and society.”
Christelle studied in France, Germany and Switzerland, receiving
a French University Diploma in Technology (DUT) in applied biology
and biochemistry, and a European Engineering degree in
biotechnology sciences. She received a Ph.D. in molecular and
cellular biology from the Institute Pasteur in France. Christelle
will continue to be based in Cambridge, Massachusetts, one of
Ipsen’s four global hubs, and will assume her new role from 22
September 2023.
ENDS
About Ipsen Ipsen is a
global, mid-sized biopharmaceutical company focused on
transformative medicines in Oncology, Rare Disease and
Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells
medicines in over 100 countries. Alongside its
external-innovation strategy, the Company’s research and
development efforts are focused on its innovative and
differentiated technological platforms located in the heart of
leading biotechnological and life-science hubs: Paris-Saclay,
France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has
around 5,300 colleagues worldwide and is listed in Paris (Euronext:
IPN) and in the U.S. through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information,
visit ipsen.com
For further information:
ContactsInvestors |
|
Craig MarksVice President, Investor Relations+44
(0)7584 349 193 |
Nicolas BoglerSenior Manager, Investor
Relations+33 6 52 19 98 92 |
Media |
|
Amy
WolfVP, Head of Corporate Brand Strategy &
Communications+41 79 576 07 23 |
Ioana
PiscociuSenior ManagerGlobal Media Relations +33 6 69 09
12 96 |
Ipsen’s forward-looking
statementsThe forward-looking statements, objectives and
targets contained herein are based on Ipsen’s management strategy,
current views and assumptions. Such statements involve known and
unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated
herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming
reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and
‘expects’ and similar expressions are intended to identify
forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen's ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des
Marchés Financiers. The risks and uncertainties set out are not
exhaustive and the reader is advised to refer to Ipsen’s latest
Universal Registration Document, available on ipsen.com.
- Ipsen PR_Christelle Huguet Appointment_01092023
Ipsen (EU:IPN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Ipsen (EU:IPN)
Gráfica de Acción Histórica
De May 2023 a May 2024